Table 3.
Associations between the CYP2D6 drugs and respective comparator drugs in patients dispensed SSRIs with (fluoxetine/paroxetine) or without (citalopram/sertraline) a pronounced inhibitory effect on CYP2D6
| SSRI | CYP2D6-drugs | Comparator drugs | Odds, CYP2D6 drugs (vs. comparator) | Odds ratios unadjusted (95% CI) | P-values | Odds ratios — adjusted for gender and age (95% CI) | P-values |
|---|---|---|---|---|---|---|---|
| Metoprolol | Atenolol | ||||||
| Fluoxetine/paroxetine | 3 164a | 2 392 | 1.32 | 0.73 (0.69, 0.78) | <0.001 | 0.80 (0.76, 0.85) | <0.001 |
| Citalopram*/sertraline | 29 058b | 16 101 | 1.80 | ||||
| Donepezil | Rivastigmine | ||||||
| Fluoxetine/paroxetine | 158c | 82 | 1.93 | 0.62 (0.47, 0.82) | <0.001 | 0.65 (0.49, 0.86) | 0.003 |
| Citalopram/sertraline | 4 546d | 1 463 | 3.11 | ||||
| Galantamine | Rivastigmine | ||||||
| Fluoxetine/paroxetine | 61e | 82 | 0.74 | 0.60 (0.43, 0.84) | 0.003 | 0.58 (0.41, 0.81) | 0.002 |
| Citalopram/sertraline | 1 823f | 1 463 | 1.25 | ||||
| Codeine | Propoxyphene | ||||||
| Fluoxetine/paroxetine | 2 322g | 1 084 | 2.14 | 1.67 (1.54, 1.80) | <0.001 | 1.03 (0.94, 1.12) | 0.559 |
| Citalopram/sertraline | 10 714h | 8 326 | 1.29 | ||||
| Tamoxifen | Anastrozole | ||||||
| Fluoxetine/paroxetine | 131i | 86 | 1.52 | 1.22 (0.92, 1.63) | 0.168 | 1.29 (0.96, 1.73) | 0.089 |
| Citalopram/sertraline | 1 017j | 817 | 1.24 |
Data are based on drug dispensing in the Swedish population (≥ 15 years of age), January to April 2008.
a
Mean defined daily dose (DDD) metoprolol (SD): 63 (48).
b
Mean DDD metoprolol (SD): 61 (46).
c
Mean DDD donepezil (SD): 118 (60).
d
Mean DDD donepezil (SD): 122 (60).
e
Mean DDD galantamine (SD): 128 (69).
f
Mean DDD galantamine (SD): 124 (60).
g
Mean DDD codeine (SD): 96 (128).
h
Mean DDD codeine (SD): 93 (117).
i
Mean DDD tamoxifen (SD): 123 (55).
j
Mean DDD tamoxifen (SD): 127 (51).